Nicholas Glover - Jul 5, 2022 Form 4 Insider Report for MEI Pharma, Inc. (MEIP)

Role
Director
Signature
/s/ Brian G. Drazba, as attorney in fact
Stock symbol
MEIP
Transactions as of
Jul 5, 2022
Transactions value $
$0
Form type
4
Date filed
7/7/2022, 04:27 PM
Previous filing
Jul 6, 2021
Next filing
Oct 12, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MEIP Stock Option (Right to Buy) Award $0 +87.5K $0.00 87.5K Jul 5, 2022 Common Stock 87.5K $0.54 Direct F1
holding MEIP Stock Option (Right to Buy) 50K Jul 5, 2022 Common Stock 50K $2.95 Direct F2
holding MEIP Stock Option (Right to Buy) 20K Jul 5, 2022 Common Stock 20K $1.57 Direct F2
holding MEIP Stock Option (Right to Buy) 40K Jul 5, 2022 Common Stock 40K $1.36 Direct F2
holding MEIP Stock Option (Right to Buy) 40K Jul 5, 2022 Common Stock 40K $2.83 Direct F2
holding MEIP Stock Option (Right to Buy) 40K Jul 5, 2022 Common Stock 40K $4.28 Direct F2
holding MEIP Stock Option (Right to Buy) 40K Jul 5, 2022 Common Stock 40K $2.52 Direct F2
holding MEIP Stock Option (Right to Buy) 50K Jul 5, 2022 Common Stock 50K $3.49 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest in equal monthly installments over twelve months.
F2 All of such options are presently exercisable.